Nipro
Biosimilar developer, Japan. 1 development product across 1 molecule: ustekinumab.
First approval in the Atlas: Dec 2025, Ustekinumab BS Nipro, ustekinumab (PMDA)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved1
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Ustekinumab | Ustekinumab BS Nipro | · | · | · | Dec 2025 | · | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with Nipro, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
AlvotechOne shared molecule: ustekinumab5 molecules in its portfolioAmgenOne shared molecule: ustekinumab8 molecules in its portfolioBio-Thera SolutionsOne shared molecule: ustekinumab3 molecules in its portfolioBiocon BiologicsOne shared molecule: ustekinumab9 molecules in its portfolioCelltrionOne shared molecule: ustekinumab10 molecules in its portfolioDong-A STOne shared molecule: ustekinumab1 molecule in its portfolio
Chronology
- PMDADec 2025Ustekinumab BS Nipro, ustekinumab
Compare Nipro with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.